Decisions regarding interruption and termination of therapy will be 
based upon the nature and severity of those events as outlined in 
Table 5 and below: 
TOXICITY GRADE 
DOSE MODIFICATION 
1 
No change 
2 
No change 
3 
No change or discontii 
therapy 
4 
Discontinue therapy 
One of the stated objectives of the protocol is to determine whether 
treatment of the patient with syngeneic peripheral blood T 
lymphocytes activated and expanded in tissue culture will have a 
positive effect on the spectrum and duration of immune reconstitution 
seen in the patient. The T lymphocytes will be recovered from the 
peripheral blood according to the schedule in Table 3 to permit 
sampling of the different immune specificities which are predominant 
at different time periods during the patient's course. Comprehensive 
immune evaluation will determine the immunologic consequences of 
the treatment given during the protocol. The inclusion and exclusion 
criterion (Sections 5.1 and 5.2) and study monitoring (Section 5.5) list 
numerous distinct immunologic characteristics which will be 
determined so that retesting will be able to accurately document 
significant changes in the patient's immune status. 
5.7 Reasons for Premature Termination of Treatment: 
5.7.1 The development of a life-threatening malignancy. 
5.7.2 Judgment of the principal investigator that termination of 
study participation is in the patient's best interest. 
5.7.3 Grade IV toxicity, grade III toxicity at the discretion of the 
principal investigator, or the development of another 
[308] 
Recombinant DNA Research, Volume 16 
